Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 242 clinical trials
The Effect of Hyperbaric Oxygen Treatment in Patients With Osteoradionecrosis.

Osteoradionecrosis (ORN) is a severe delayed radiation-induced injury that can occur in patients whom have been subjected to radiotherapy for head and neck cancer. Hyperbaric oxygen treatment (HBO) is one treatment option. In Sweden it is used in some locations in combination to standard treatment which includes for example antibiotics, …

  • 0 views
  • 28 Jun, 2021
  • 2 locations
Digitally Distributed Yoga for Women Treated for Breast Cancer (DigiyogaCare)

Breast cancer is the most common cancer disease in women. As the prevalence of fatigue is high in this group it is motivated to find interventions that can reduce fatigue and render in an increased level of physical activity both during and after treatment. Yoga have shown effect on cancer …

  • 0 views
  • 11 Mar, 2022
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Rad2Nivo)

This is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.

gilbert's syndrome
platelet count
bone metastases
testosterone
adenocarcinoma
  • 0 views
  • 03 May, 2022
  • 1 location
FITMI - First In Treating Male Infertility

This RCT aims to assess whether treatment with Denosumab can improve semen quality in infertile men selected by serum AMH as a positive predictive biomarker.

  • 0 views
  • 21 Mar, 2022
  • 1 location
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.

bisphosphonate
ct scan
bone metastases
castration-resistant prostate cancer
breast cancer
  • 72 views
  • 21 Apr, 2022
  • 62 locations
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

This research study is being done to find out if giving zoledronic acid before the cancer spreads to the bone is better or worse than standard treatment. The study will also compare the effects (good and bad) of early treatment with zoledronic acid compared to standard treatment. In this study …

zoledronic acid
bone metastases
zoledronate
cancer
  • 41 views
  • 07 Nov, 2020
  • 1 location
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

. Patients in Group 1 should have up to 6 bone metastases and patients for group 2 should have more than 6 bone metastases. The study medication will be given as injection into a vein every 4 weeks up to a

  • 0 views
  • 05 Jul, 2022
  • 9 locations
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)

In patients with a limited oligometastatic burden (cancer has spread but is not yet considered metastatic), emerging evidence suggests that treatment of all sites of disease with ablative therapies can improve patient outcomes, including overall- and progression-free survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10 metastatic …

metastasis
cancer
primary tumor
stereotactic body radiation therapy
  • 42 views
  • 27 Apr, 2022
  • 12 locations
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) …

metastasis
positron emission tomography
primary tumor
cancer
bone scan
  • 88 views
  • 06 May, 2022
  • 14 locations
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this …

docetaxel
cancer
atezolizumab
paclitaxel
trastuzumab
  • 353 views
  • 13 Jun, 2022
  • 1 location